A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis

This is a dose finding study to evaluate the safety and determine the maximum tolerated dose of carfilzomib in patients with previously treated systemic light-chain amyloidosis.

Principal Investigator

CONTACT INFORMATION

Primary Contact:
Ying Hao
(650) 723-0646